Skip to main content
SpringerLink
Log in

Hemopoietic Cell Transplantation

  • Chapter
Book cover Hematologic Malignancies: Myelodysplastic Syndromes

Part of the book series: Hematologic Malignancies ((HEMATOLOGIC))

  • 658 Accesses

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 139.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Anderson JE, Appelbaum FR, Schoch G, Gooley T, Anasetti C, Bensinger WI, Bryant E, Buckner CD, Chauncey T, Clift RA, Deeg HJ, Doney K, Flowers M, Hansen JA, Martin PJ, Matthews DC, Nash RA, Sanders JE, Shulman H, Sullivan KM, Witherspoon RP, Storb R (1996) Allogeneic marrow transplantation for myelodysplastic syndrome with advanced disease morphology: a phase II study of busulfan, cyclophosphamide, and total-body irradiation and analysis of prognostic factors. J Clin Oncol 14:220–226

    PubMed  CAS  Google Scholar 

  • Appelbaum FR, Anderson J (1998) Allogeneic bone marrow transplantation for myelodysplastic syndrome: outcomes analysis according to IPSS score. Leukemia 12[Suppl 1]:S25–S29

    PubMed  Google Scholar 

  • Appelbaum FR, Barrall J, Storb R, Fisher LD, Schoch G, Ramberg RE, Shulman H, Anasetti C, Bearman SI, Beatty P, Bensinger WI, Buckner CD, Clift RA, Hansen JA, Martin P, Petersen FB, Sanders JE, Singer J, Stewart P, Sullivan KM, Witherspoon RP, Thomas ED (1990) Bone marrow transplantation for patients with myelodysplasia. Pretreatment variables and outcome. Ann Intern Med 112:590–597

    PubMed  CAS  Google Scholar 

  • Arnold R, de Witte T, van Biezen A, Hermans J, Jacobsen N, Runde V, Gratwohl A, Apperley JF (1998) Unrelated bone marrow transplantation in patients with myelodysplastic syndromes and secondary acute myeloid leukemia: an EBMT survey. European Blood and Marrow Transplantation Group. Bone Marrow Transplant 21: 1213–1216

    Article  PubMed  CAS  Google Scholar 

  • Bader P, Klingebiel T, Schaudt A, Theurer-Mainka U, Handgretinger R, Lang P, Niethammer D, Beck JF (1999) Prevention of relapse in pediatric patients with acute leukemias and MDS after allogeneic SCT by early immunotherapy initiated on the basis of increasing mixed chimerism: a single center experience of 12 children. Leukemia 13:2079–2086

    PubMed  CAS  Google Scholar 

  • Ballen KK, Gilliland DG, Guinan EC, Hsieh CC, Parsons SK, Rimm IJ, Ferrara JL, Bierer BE, Weinstein HJ, Antin JH (1997) Bone marrow transplantation for therapy-related myelodysplasia: comparison with primary myelodysplasia. Bone Marrow Transplant 20:737–743

    Article  PubMed  CAS  Google Scholar 

  • Benesch M, Wells DA, Leisenring W, Loken MR, Myerson D, Deeg HJ (2002) Prognostic significance of pretransplant multidimensional flow cytometric parameters for posttransplant survival and relapse in 111 patients with myelodysplastic syndrome (MDS) [Abstract]. Blood 100:97 a

    Google Scholar 

  • Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DAG, Gralnick HR, Sultan C, The French-American-British (FAB) Co-Operative Group (1982) Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 51:189–199

    PubMed  CAS  Google Scholar 

  • Bethge WA, Hegenbart U, Stuart MJ, Storer BE, Maris MB, Flowers MED, Maloney DG, Chauncey T, Bruno B, Agura E, Forman SJ, Blume KG, Niederweiser D, Storb R, Sandmaier BM (2004) Adoptive immunotherapy with donor lymphocyte infusions after allogeneic hematopoietic cell transplantation following nonmyeloablative conditioning. Blood 103:790–795

    PubMed  CAS  Google Scholar 

  • Bornhäuser M, Storer B, Slattery JT, Appelbaum FR, Deeg HJ, Hansen J, Martin PJ, McDonald GB, Nichols G, Radich J, Woolfrey A, Jenke A, Schleyer E, Thiede C, Ehninger G, Anasetti C (2003) Conditioning with fludarabine and targeted busulfan for transplantation of allogeneic hematopoietic stem cells. Blood 102:820–826

    PubMed  Google Scholar 

  • Carella AM, Champlin R, Slavin S, McSweeney P, Storb R (2000) Miniallografts: ongoing trials in humans (Editorial). Bone Marrow Transplant 25:345–350

    Article  PubMed  CAS  Google Scholar 

  • Castagna L, El Weshi A, Bourhis JH, Ribrag V, Naccache P, Vantelon JM, Brault P, Pico JL (1998) Successful donor lymphocyte infusion (DLI) in a patient with myelodysplastic syndrome (MDS) after failure of T-cell-depleted bone marrow transplantation (TD-BMT) (Letter). Br J Haematol 103:284–285

    Article  PubMed  CAS  Google Scholar 

  • Castro-Malaspina H, Harris RE, Gajewski J, Ramsay N, Collins R, Dharan B, King R, Deeg HJ (2002) Unrelated donor marrow transplantation for myelodysplastic syndromes: outcome analysis in 510 transplants facilitated by the National Marrow Donor Program. Blood 99:1943–1951

    Article  PubMed  CAS  Google Scholar 

  • Chan GW, Foss FM, Klein AK, Sprague K, Miller KB (2003) Reduced-intensity transplantation for patients with myelodysplastic syndrome achieves durable remission with less graft-versus-host disease. Biol Blood Marrow Transplant 9:753–759

    PubMed  Google Scholar 

  • Cutler CS, Lee SJ, Greenberg P, Deeg HJ, Pérez WS, Anasetti C, Bolwell BJ, Cairo MS, Gale RP, Klein JP, Lazarus HM, Liesveld JL, McCarthy PL, Milone GA, Rizzo JD, Schultz KR, Trigg ME, Keating A, Weisdorf DJ, Antin JH, Horowitz MM (2004) A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome. Blood 104:579–585

    Article  PubMed  CAS  Google Scholar 

  • de Lima M, Anagnostopoulos A, Munsell M, Shahjahan M, Ueno N, Ippoliti C, Andersson BS, Gajewski J, Couriel D, Cortes J, Donato M, Neumann J, Champlin R, Giralt S (2004) Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation. Blood 104:865–872

    PubMed  Google Scholar 

  • de Witte T (1999) Stem cell transplantation in myelodysplastic syndromes (Review). Forum 9:75–81

    PubMed  Google Scholar 

  • de Witte T, van Biezen A, Hermans J, Labopin M, Runde V, Or R, Meloni G, Mauri SB, Carella A, Apperley J, Gratwohl A, Laporte J-P (1997) Autologous bone marrow transplantation for patients with myelodysplastic syndrome (MDS) or acute myeloid leukemia following MDS. Blood 90:3853–3857

    PubMed  Google Scholar 

  • de Witte T, Suciu S, Verhoef G, Labar B, Archimbaud E, Aul C, Selleslag D, Ferrant A, Wijermans P, Mandelli F, Amadori S, Jehn U, Muus P, Boogaerts M, Zittoun R, Gratwohl A, Zwierzina H, Hagemeijer A, Willemze R (2001) Intensive chemotherapy followed by allogeneic or autologous stem cell transplantation for patients with myelodysplastic syndromes (MDSs) and acute myeloid leukemia following MDS. Blood 98:2326–2331

    PubMed  Google Scholar 

  • Deeg HJ, Shulman HM, Anderson JE, Bryant EM, Gooley TA, Slattery JT, Anasetti C, Fefer A, Storb R, Appelbaum FR (2000) Allogeneic and syngeneic marrow transplantation for myelodysplastic syndrome in patients 55 to 66 years of age. Blood 95:1188–1194

    PubMed  CAS  Google Scholar 

  • Deeg HJ, Storer B, Slattery JT, Anasetti C, Doney KC, Hansen JA, Kiem H-P, Martin PJ, Petersdorf E, Radich JP, Sanders JE, Shulman HM, Warren EH, Witherspoon RP, Bryant EM, Chauncey TR, Getzendaner L, Storb R, Appelbaum FR (2002) Conditioning with targeted busulfan and cyclophosphamide for hemopoietic stem cell transplantation from related and unrelated donors in patients with myelodysplastic syndrome. Blood 100:1201–1207

    Article  PubMed  CAS  Google Scholar 

  • Deeg HJ, Appelbaum FR, Storer B, Cassarella M, Scott B, McDonald G, Storb R (2004a) Reduced incidence of acute and chronic graft-versus-host disease (GvHD) without increased relapse in patients with high-risk myeloid disorders given thymoglobulin (THY) as part of the transplant conditioning regimen: a dose finding study [Abstract]. Blood 104:56 a

    Google Scholar 

  • Deeg HJ, Jiang PYZ, Holmberg LA, Scott B, Petersdorf EW, Appelbaum FR (2004 b) Hematologic responses of patients with MDS to antithymocyte globulin plus etanercept correlate with improved flow scores of marrow cells. Leuk Res 28:1177–1180

    Article  PubMed  Google Scholar 

  • Depil S, Deconinck E, Milpied N, Sutton L, Witz F, Jouet JP, Damaj G, Yakoub-Agha I (2004) Donor lymphocyte infusion to treat relapse after allogeneic bone marrow transplantation for myelodysplastic syndrome. Bone Marrow Transplant 33:531–534

    Article  PubMed  CAS  Google Scholar 

  • Friedberg JW, Neuberg D, Stone RM, Alyea E, Jallow H, LaCasce A, Mauch PM, Gribben JG, Ritz J, Nadler LM, Soiffer RJ, Freedman AS (1999) Outcome in patients with myelodysplastic syndrome after autologous bone marrow transplantation for non-Hodgkin’s lymphoma. J Clin Oncol 17:3128–3135

    PubMed  CAS  Google Scholar 

  • Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G, Sanz M, Vallespi T, Hamblin T, Oscier D, Ohyashiki K, Toyama K, Aul C, Mufti G, Bennett J (1997) International scoring system for evaluating prognosis in myelodysplastic syndromes (erratum appears in Blood 1998 91:1100). Blood 89:2079–2088

    PubMed  CAS  Google Scholar 

  • Guardiola P, Runde V, Bacigalupo A, Ruutu T, Locatelli F, Boogaerts MA, Pagliuca A, Cornelissen JJ, Schouten HC, Carreras E, Finke J, van Biezen A, Brand R, Niederwieser D, Gluckman E, de Witte TM, Subcommittee for Myelodysplastic Syndromes of the Chronic Leukaemia Working Group of the European Blood and Marrow Transplantation Group (2002) Retrospective comparison of bone marrow and granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells for allogeneic stem cell transplantation using HLA identical sibling donors in myelodysplastic syndromes. Blood 99:4370–4378

    Article  PubMed  CAS  Google Scholar 

  • Ho AYL, Pagliuca A, Kenyon M, Parker JE, Mijovic A, Devereux S, Mufti GJ (2004) Reduced-intensity allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome and acute myeloid leukemia with multilineage dysplasia using fludarabine, busulphan and alemtuzumab (FBC) conditioning. Blood 104:1616–1623

    PubMed  CAS  Google Scholar 

  • Jurado M, Deeg HJ, Storer B, Anasetti C, Anderson JE, Bryant E, Chauncey T, Doney K, Flowers MED, Hansen J, Martin PJ, Nash RA, Petersdorf E, Radich J, Sale G, Sandmaier BM, Storb R, Wade J, Witherspoon R, Appelbaum FR (2002) Hematopoietic stem cell transplantation for advanced myelodysplastic syndrome after conditioning with busulfan and fractionated total body irradiation is associated with low relapse rate but considerable nonrelapse mortality. Biol Blood Marrow Transplant 8:161–169

    Article  PubMed  Google Scholar 

  • Kroger N, Schetelig J, Zabelina T, Kruger W, Renges H, Stute N, Schrum J, Kabisch H, Siegert W, Zander AR (2001) A fludarabine-based dose-reduced conditioning regimen followed by allogeneic stem cell transplantation from related or unrelated donors in patients with myelodysplastic syndrome. Bone Marrow Transplant 28:643–647

    PubMed  CAS  Google Scholar 

  • Kroger N, Bornhauser M, Ehninger G, Schwerdtfeger R, Biersack H, Sayer HG, Wandt H, Schafer-Eckardt K, Beyer J, Kiehl M, Zander AR (2003) Allogeneic stem cell transplantation after a fludara-bine/busulfan-based reduced-intensity conditioning in patients with myelodysplastic syndrome or secondary acute myeloid leukemia. Ann Hematol 82:336–342

    PubMed  CAS  Google Scholar 

  • List A, Beran M, DiPersio J, Slack J, Vey N, Rosenfeld CS, Greenberg P (2003) Opportunities for Trisenox (arsenic trioxide) in the treatment of myelodysplastic syndromes. Leukemia 17:1499–1507

    Article  PubMed  CAS  Google Scholar 

  • Martino R, van Biezen A, Iacobelli S, Brand R, Niederwieser DW, de Witte TM (2003) Reduced-intensity conditioning (RIC) for allogeneic hematopoietic stem cell transplantation (HSCT) from HLA-identical siblings in adults with myelodysplastic syndromes (MDS): a comparison with standard myeloablative conditioning: a study of the EBMT-Chronic Leukemia Working Party (EBMT-CLWP) [Abstract]. Blood 102:184 a

    Google Scholar 

  • Maschek H, Georgii A, Kaloutsi V, Werner M, Bandecar K, Kressel M-G, Choritz H, Freund M, Hufnagl D (1992) Myelofibrosis in primary myelodysplastic syndromes: a retrospective study of 352 patients. Eur J Haematol 48:208–214

    PubMed  CAS  Google Scholar 

  • McSweeney PA, Storb R (1999) Mixed chimerism: preclinical studies and clinical applications (Review). Biol Blood Marrow Transplant 5:192–203

    Article  PubMed  CAS  Google Scholar 

  • Micallef INM, Lillington DM, Apostolidis J, Amess JAL, Neat M, Matthews J, Clark T, Foran JM, Salam A, Lister A, Rohatiner AZS (2000) Therapy-related myelodysplasia and secondary acute myelogenous leukemia after high-dose therapy with autologous hematopoietic progenitor-cell support for lymphoid malignancies. J Clin Oncol 18:947–955

    PubMed  CAS  Google Scholar 

  • Molldrem JJ, Leifer E, Bahceci E, Saunthararajah Y, Rivera M, Dunbar C, Liu J, Nakamura R, Young NS, Barrett AJ (2002) Antithymocyte globulin for treatment of the bone marrow failure associated with myelodysplastic syndrome [summary for patients in Ann Intern Med 2002 137:1–27]. Ann Intern Med 137:156–163

    PubMed  Google Scholar 

  • Nevill TJ, Fung HC, Shepherd JD, Horsman DE, Nantel SH, Klingemann HG, Forrest DL, Toze CL, Sutherland HJ, Hogge DE, Naiman SC, Le A, Brockington DA, Barnett MJ (1998) Cytogenetic abnormalities in primary myelodysplastic syndrome are highly predictive of outcome after allogeneic bone marrow transplantation. Blood 92:1910–1917

    PubMed  CAS  Google Scholar 

  • O’Donnell MR, Long GD, Parker PM, Niland J, Nademanee A, Amylon M, Chao N, Negrin RS, Schmidt GM, Slovak ML, Smith EP, Snyder DS, Stein AS, Traweek T, Blume KG, Forman SJ (1995) Busulfan/cyclophosphamide as conditioning regimen for allogeneic bone marrow transplantation for myelodysplasia. J Clin Oncol 13:2973–2979

    PubMed  CAS  Google Scholar 

  • Oosterveld M, Suciu S, Verhoef G, Labar B, Belhabri A, Aul C, Selleslag D, Ferrant A, Wijermans P, Mandelli F, Amadori S, Jehn U, Muus P, Zittoun R, Hess U, Anak O, Beeldens F, Willemze R, de Witte T (2003) The presence of an HLA-identical sibling donor has no impact on outcome of patients with high-risk MDS or secondary AML (sAML) treated with intensive chemotherapy followed by transplantation: results of a prospective study of the EORTC, EBMT, SAKK and GIMEMA Leukemia Groups (EORTC study 06921). Leukemia 17:859–868

    PubMed  CAS  Google Scholar 

  • Parker JE, Shafi T, Pagliuca A, Mijovic A, Devereux S, Potter M, Prentice HG, Garg M, Yin JA, Byrne J, Russell NH, Mufti GJ (2002) Allogeneic stem cell transplantation in the myelodysplastic syndromes: interim results of outcome following reduced-intensity conditioning compared with standard preparative regimens. Br J Haematol 119:144–154

    Article  PubMed  Google Scholar 

  • Ratanatharathorn V, Karanes C, Uberti J, Lum LG, de Planque MM, Schultz KR, Cronin S, Dan ME, Mohamed A, Hussein M, Sensenbrenner LL (1993) Busulfan-based regimens and allogeneic bone marrow transplantation in patients with myelodysplastic syndromes. Blood 81:2194–2199

    PubMed  CAS  Google Scholar 

  • Raza A, Meyer P, Dutt D, Zorat F, Lisak L, Nascimben F, du R M, Kaspar C, Goldberg C, Loew J, Dar S, Gezer S, Venugopal P, Zeldis J (2001) Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes. Blood 98:958–965

    PubMed  CAS  Google Scholar 

  • Runde V, de Witte T, Arnold R, Gratwohl A, Hermans J, van Biezen A, Niederwieser D, Labopin M, Walter-Noel MP Bacigalupo A, Jacobsen N, Ljungman P, Carreras E, Kolb HJ, Aul C, Apperley J (1998) Bone marrow transplantation from HLA-identical siblings as first-line treatment in patients with myelodysplastic syndromes: early transplantation is associated with improved outcome. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 21:255–261

    Article  PubMed  CAS  Google Scholar 

  • Russell JA, Tran HT, Quinlan D, Chaudhry A, Duggan P, Brown C, Stewart D, Ruether JD, Morris D, Glick S, Gyonyor E, Andersson BS (2002) Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes. Biol Blood Marrow Transplant 8:468–476

    Article  PubMed  CAS  Google Scholar 

  • Scott BL, Maris M, Sandmaier B, Storer B, Chauncey T, Maloney DG, Sorror M, Storb R, Deeg HJ (2004) Myeloablative versus nonmyeloablative hemopoietic cell transplantation (HCT) for patients with myelodysplasia (MDS) or AML with multilineage dysplasia following MDS (tAML) [Abstract]. Blood 104:638 a

    Article  Google Scholar 

  • Scott BL, Storer B, Loken M, Storb R, Appelbaum FR, Deeg HJ (2005) Pretransplantation induction chemotherapy and posttransplantation relapse in patients with advanced myelodysplastic syndrome. Biol Blood Marrow Transplant 11:65–73

    Article  PubMed  Google Scholar 

  • Shiobara S, Nakao S, Ueda M, Yamazaki H, Takahashi S, Asano S, Yabe H, Kato S, Imoto S, Maruta A, Yoshida T, Gondo H, Morishima Y, Kodera Y (2000) Donor leukocyte infusion for Japanese patients with relapsed leukemia after allogeneic bone marrow transplantation: lower incidence of acute graft-versus-host disease and improved outcome. Bone Marrow Transplant 26:769–774

    Article  PubMed  CAS  Google Scholar 

  • Sierra J, Pérez WS, Rozman C, Carreras E, Klein JP, Rizzo JD, Davies SM, Lazarus HM, Bredeson CN, Marks DI, Canals C, Boogaerts MA, Goldman J, Champlin RE, Keating A, Weisdorf DJ, de Witte TM, Horowitz MM (2002) Bone marrow transplantation from HLA-identical siblings as treatment for myelodysplasia. Blood 100: 1997–2004

    PubMed  CAS  Google Scholar 

  • Silverman LR, Demakos EP, Peterson BL, Kornblith AB, Holland JC, Odchimar-Reissig R, Stone RM, Nelson D, Powell BL, DeCastro CM, Ellerton J, Larson RA, Schiffer CA, Holland JF (2002) Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. JClin Oncol 20:2429–2440

    CAS  Google Scholar 

  • Sobecks RM, Le Beau MM, Anastasi J, Williams SF (1999) Myelodysplasia and acute leukemia following high-dose chemotherapy and autologous bone marrow or peripheral blood stem cell transplantation. Bone Marrow Transplant 23:1161–1165

    Article  PubMed  CAS  Google Scholar 

  • Storb R, McSweeney PA, Sandmaier BM, Nash RA, Georges G, Maloney DG, Molina A, Chauncey T, Yu C, Zaucha JM, Blume KG, Shizuru J, Niederwieser D (2000) Allogeneic hematopoietic stem cell transplantation: from the nuclear age into the 21st century. Transplant Proc 32:2548–2549

    Article  PubMed  CAS  Google Scholar 

  • Stuart MJ, Cao TM, Sandmaier BM, Hegenbart U, Maris M, Agura E, Chauncey TR, Maloney DG, Pulsipher MA, Wong R, Niederwieser DW, Blume KG, Storb RF (2003) Efficacy of non-myeloablative allogeneic transplant for patients with myelodysplastic syndrome (MDS) and myeloproliferative disorders (MPD) (except chronic myelogenous leukemia) [Abstract]. Blood 102:185 a

    Google Scholar 

  • Taussig DC, Davies AJ, Cavenagh JD, Oakervee H, Syndercombe-Court D, Kelsey S, Amess JA, Rohatiner AZ, Lister TA, Barnett MJ (2003) Durable remissions of myelodysplastic syndrome and acute myeloid leukemia after reduced-intensity allografting. J Clin Oncol 21:3060–3065

    Article  PubMed  CAS  Google Scholar 

  • Vardiman JW, Harris NL, Brunning RD (2002) The World Health Organization (WHO) classification of the myeloid neoplasms (Review). Blood 100:2292–2302

    Article  PubMed  CAS  Google Scholar 

  • Wattel E, Solary E, Leleu X, Dreyfus F, Brion A, Jouet JP, Hoang-Ngoc L, Maloisel F, Guerci A, Rochant H, Gratecos N, Casassus P, Janvier M, Brice P, Lepelley P, Fenaux P (1999) A prospective study of autologous bone marrow or peripheral blood stem cell transplantation after intensive chemotherapy in myelodysplastic syndromes. Leukemia 13:524–529

    PubMed  CAS  Google Scholar 

  • Wells DA, Benesch M, Loken MR, Vallejo C, Myerson D, Leisenring WM, Deeg HJ (2003) Myeloid and monocytic dyspoiesis as determined by flow cytometric scoring in myelodysplastic syndrome correlates with the IPSS and with outcome after hemopoietic stem cell transplantation. Blood 102:394–403

    Article  PubMed  CAS  Google Scholar 

  • Witherspoon RP, Deeg HJ, Storer B, Anasetti C, Storb R, Appelbaum FR (2001) Hematopoietic stem-cell transplantation for treatment-related leukemia or myelodysplasia. J Clin Oncol 19:2134–2141

    PubMed  CAS  Google Scholar 

  • Yakoub-Agha I, de La Salmonière P, Ribaud P, Sutton L, Wattel E, Kuentz M, Jouet JP, Marit G, Milpied N, Deconinck E, Gratecos N, Leporrier M, Chabbert I, Caillot D, Damaj G, Dauriac C, Dreyfus F, FranÇois S, Molina L, Tanguy ML, Chevret S, Gluckman E (2000) Allogeneic bone marrow transplantation for therapy-related myelodysplastic syndrome and acute myeloid leukemia: a long-term study of 70 patients-report of the French Society of bone marrow transplantation. J Clin Oncol 18:963–971

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue North, D1-100, P.O. Box 19024, Seattle, WA, 98109-1024, USA

    Bart Scott M. D. & H. Joachim Deeg M. D.

Authors
  1. Bart Scott M. D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. H. Joachim Deeg M. D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2006 Springer Berlin Heidelberg

About this chapter

Cite this chapter

Scott, B., Deeg, H.J. (2006). Hemopoietic Cell Transplantation. In: Hematologic Malignancies: Myelodysplastic Syndromes. Hematologic Malignancies. Springer, Berlin, Heidelberg. https://doi.org/10.1007/3-540-30794-X_12

Download citation

  • DOI: https://doi.org/10.1007/3-540-30794-X_12

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-26188-9

  • Online ISBN: 978-3-540-30794-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation